Literature DB >> 21415203

Evidence for persisters in Staphylococcus epidermidis RP62a planktonic cultures and biofilms.

Julie A Shapiro1, Valerie L Nguyen1, Neal R Chamberlain1.   

Abstract

The pathogenesis of Staphylococcus epidermidis in foreign device-related infections is attributed primarily to its ability to form biofilms on a polymer surface. One mechanism proposed for the survival of organisms in a biofilm is the presence of persister cells. Persister cells survive antibiotic treatment without acquiring heritable antibiotic resistance. This study was conducted to determine if S. epidermidis RP62a growing in planktonic cultures and biofilms could survive as persister cells following treatment with levofloxacin and vancomycin. S. epidermidis RP62a produced a small percentage of persisters (levofloxacin, 3.09×10⁻⁷%; vancomycin, 8.21×10⁻⁵ %) when grown to exponential phase, whereas biofilms contained 28 and 94 % persisters, following exposure to levofloxacin and vancomycin, respectively. The highest percentages of persisters were obtained during stationary phase in planktonic cultures and the lowest percentages of persisters were obtained during mid-exponential phase. An increase in persister number was not due to activation of quorum-sensing regulons. Confocal laser scanning microscopy images of biofilms exposed to levofloxacin demonstrated that the antibiotic was able to kill bacteria throughout the biofilm. Our results suggest that antibiotic tolerance in biofilms and in planktonic cultures of S. epidermidis RP62a is due in part to the presence of persister cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415203     DOI: 10.1099/jmm.0.026013-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  18 in total

1.  The relative contributions of physical structure and cell density to the antibiotic susceptibility of bacteria in biofilms.

Authors:  Amy E Kirby; Kimberly Garner; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

2.  Antimicrobial Tolerance in Biofilms.

Authors:  Philip S Stewart
Journal:  Microbiol Spectr       Date:  2015-06

3.  A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus.

Authors:  Lukas Mechler; Alexander Herbig; Kerstin Paprotka; Martin Fraunholz; Kay Nieselt; Ralph Bertram
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

Review 4.  Molecular basis of Staphylococcus epidermidis infections.

Authors:  Michael Otto
Journal:  Semin Immunopathol       Date:  2011-11-19       Impact factor: 9.623

5.  Staphylococcus aureus persisters tolerant to bactericidal antibiotics.

Authors:  Sabrina Lechner; Kim Lewis; Ralph Bertram
Journal:  J Mol Microbiol Biotechnol       Date:  2012-09-14

6.  An evaluation of the bacteriostatic effect of platelet-rich plasma.

Authors:  Oliver J Smith; Aditya Wicaksana; Donald Davidson; David Spratt; Ash Mosahebi
Journal:  Int Wound J       Date:  2021-01-21       Impact factor: 3.315

7.  Confocal laser scanning microscopy analysis of S. epidermidis biofilms exposed to farnesol, vancomycin and rifampicin.

Authors:  Nuno Cerca; Fernanda Gomes; Sofia Pereira; Pilar Teixeira; Rosário Oliveira
Journal:  BMC Res Notes       Date:  2012-05-16

8.  Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters.

Authors:  Iris Keren; Shoko Minami; Eric Rubin; Kim Lewis
Journal:  MBio       Date:  2011-06-14       Impact factor: 7.867

9.  Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus.

Authors:  Paul J T Johnson; Bruce R Levin
Journal:  PLoS Genet       Date:  2013-01-03       Impact factor: 5.917

10.  Staphylococcus epidermidis Has Growth Phase Dependent Affinity for Fibrinogen and Resulting Fibrin Clot Elasticity.

Authors:  Carolyn Vitale; Tianhui Maria Ma; Janice Sim; Christopher Altheim; Erika Martinez-Nieves; Usha Kadiyala; Michael J Solomon; J Scott VanEpps
Journal:  Front Microbiol       Date:  2021-06-16       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.